Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
Open Access
- 25 March 2023
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 33 (5), 3416-3424
- https://doi.org/10.1007/s00330-023-09518-y
Abstract
Objectives The recently proposed standardized reporting and data system for somatostatin receptor (SSTR)–targeted PET/CT SSTR-RADS 1.0 showed promising first results in the assessment of diagnosis and treatment planning with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). This study aimed to determine the intra- and interreader agreement of SSTR-RADS 1.0. Methods SSTR-PET/CT scans of 100 patients were independently evaluated by 4 readers with different levels of expertise according to the SSTR-RADS 1.0 criteria at 2 time points within 6 weeks. For each scan, a maximum of five target lesions were freely chosen by each reader (not more than three lesions per organ) and stratified according to the SSTR-RADS 1.0 criteria. Overall scan score and binary decision on PRRT were assessed. Intra- and interreader agreement was determined using the intraclass correlation coefficient (ICC). Results Interreader agreement using SSTR-RADS 1.0 for identical target lesions (ICC ≥ 0.91) and overall scan score (ICC ≥ 0.93) was excellent. The decision to state “functional imaging fulfills requirements for PRRT and qualifies patient as potential candidate for PRRT” also demonstrated excellent agreement among all readers (ICC ≥ 0.86). Intrareader agreement was excellent even among different experience levels when comparing target lesion–based scores (ICC ≥ 0.98), overall scan score (ICC ≥ 0.93), and decision for PRRT (ICC ≥ 0.88). Conclusion SSTR-RADS 1.0 represents a highly reproducible and accurate system for stratifying SSTR-targeted PET/CT scans with high intra- and interreader agreement. The system is a promising approach to standardize the diagnosis and treatment planning in NET patients. Key Points • SSTR-RADS 1.0 offers high reproducibility and accuracy. • SSTR-RADS 1.0 is a promising method to standardize diagnosis and treatment planning for patients with NET.Funding Information
- Universitätsklinik München
This publication has 24 references indexed in Scilit:
- 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective StudyJournal of Nuclear Medicine, 2017
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsThe New England Journal of Medicine, 2017
- 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 PatientsJournal of Nuclear Medicine, 2016
- Somatostatin Receptor Imaging with68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in InterpretationRadioGraphics, 2015
- Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Role of 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumoursEuropean Radiology, 2011
- Distribution pattern of 68Ga-DOTATATE in disease-free patientsNuclear Medicine Communications, 2010
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumorsEndocrine-Related Cancer, 2010
- Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumoursActa Oncologica, 2007
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993